TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Checkpoint inhibitors are effective in a subset of cancer patients, particularly those with T cell-infiltrated tumors.
• Low response rates in other patients necessitate strategies to enhance immunotherapy sensitization.
• Colorectal cancer (CRC) remains a significant health concern with ongoing research into novel therapeutic approaches.

Purpose of the Study:

• To investigate the potential of Traf2 and Nck-interacting protein kinase inhibitors (TNIKi) to sensitize colorectal cancer to immunotherapy.
• To elucidate the mechanisms by which TNIKi influences the tumor microenvironment and T cell response.
• To evaluate the efficacy of combining TNIKi with PD-1 checkpoint inhibitors in preclinical CRC models.

Main Methods:

• Utilized various colorectal cancer mouse models.
• Administered Traf2 and Nck-interacting protein kinase inhibitors (TNIKi) alone and in combination with PD-1 checkpoint inhibitors.
• Assessed tumor infiltration by PD-1+ CD8+ T cells.
• Investigated mechanisms including immunogenic cell death and direct CD8 T cell activation.

Main Results:

• TNIKi unexpectedly increased tumor infiltration by PD-1+ CD8+ T cells.
• Two independent mechanisms were identified: induction of immunogenic cell death and direct CD8 T cell activation.
• Combination therapy with TNIKi and PD-1 inhibitors achieved complete tumor control in 50% of mice.
• Demonstrated immunogenic properties of TNIKi in the context of immunotherapy.

Conclusions:

• TNIKi exhibits immunogenic properties that can enhance anti-tumor immune responses.
• Combining TNIKi with PD-1 checkpoint inhibitors significantly improves tumor control in colorectal cancer models.
• This combination strategy holds potential for increasing the proportion of colorectal cancers responsive to checkpoint therapy.